Reach your audience. Get results.
Rely on the experience, guidance, and superior media targeting of Business Wire for your global press release distribution.
Public RelationsMaximize the reach of your news with our press release distribution services and partnerships. Investor RelationsReach and engage investors, shareholders, analysts, and media with our complete suite of IR services and tools. Distribution & AnalyticsTarget your news, reach your audiences, and understand the impact of your press releases with our analytics reports. |
Latest News
Today is September 25, 2024.
All times in Eastern Daylight Time.
-
Samenvatting: Nieuwe gegevens tonen aan dat EBGLYSS® (lebrikizumab) van Almirall tot drie jaar lang standvastige controle van de ziekte opleverde bij meer dan 80% van de volwassenen en adolescenten met matige tot ernstige atopische dermatitisBARCELONA, Spanje--(BUSINESS WIRE)--Meer dan 80 procent van de volwassenen en adolescenten met matige tot ernstige atopische dermatitis die reageerden op de behandeling met lebrikizumab tijdens wee... more »
-
Riassunto: Nuovi dati dimostrano che EBGLYSS® (Lebrikizumab) di Almirall assicura un controllo duraturo della malattia fino a tre anni in oltre l'80% degli adulti e degli adolescenti con dermatite atopica da moderata a graveBARCELLONA, Spagna--(BUSINESS WIRE)--Oltre l'80% degli adulti e degli adolescenti con dermatite atopica da moderata a grave che hanno risposto al trattamento con lebrikizumab alla settimana 16 negl... more »
-
De nouvelles données montrent qu'EBGLYSS® (Lebrikizumab) d'Almirall a contrôlé la maladie pendant trois ans chez plus de 80 % des adultes et des adolescents atteints de dermatite atopique modérée à sévèreBARCELONE, Espagne--(BUSINESS WIRE)--Plus de 80 % des adultes et des adolescents affectés par une dermatite atopique modérée à sévère qui ont réagi au traitement par lebrikizumab lors de la 16ᵉ sem... more »
-
Resumen: Nuevos datos demuestran que EBGLYSS® (lebrikizumab) de Almirall brindó un control de la enfermedad sostenido durante un máximo de tres años en más del 80 % de los adultos y adolescentes con dermatitis atópica moderada o graveBARCELONA, España--(BUSINESS WIRE)--Más del 80 por ciento de los adultos y adolescentes con dermatitis atópica moderada o grave que respondieron a un tratamiento con lebrikizumab en la semana 16 en... more »
-
Neuen Daten zufolge bewirkt EBGLYSS® (Lebrikizumab) von Almirall eine nachhaltige Linderung bei mehr als 80 % der Erwachsenen und Jugendlichen mit mittelschwerer bis schwerer atopischer Dermatitis nach einer Behandlung von bis zu 3 JahrenBARCELONA, Spanien--(BUSINESS WIRE)--Bei mehr als 80 Prozent der Erwachsenen und Jugendlichen mit mittelschwerer bis schwerer atopischer Dermatitis, die in den Monotherapie-Studien ADvocate 1 und 2... more »
-
易受攻击的API和机器人攻击每年给企业造成高达1860亿美元的损失法国默东--(BUSINESS WIRE)--(美国商业资讯)-- 作为全球网络安全领域的领导者之一,泰雷兹致力于为关键应用程序、API和数据提供大规模保护。该公司近日发布了《 API和机器人攻击的经济影响 》报告,分析了超过16.1万起独特的网络安全事件,揭示了易受攻击或不安全的API和机器人的自动滥用这两大安全威胁日益紧密且普遍所带来的全球损失。据该报告估计,API的不安全性和机器人攻击... more »
-
TDWP Announces Deal with Summit Next Gen and Provides a Strategic UpdateHOUSTON--(BUSINESS WIRE)--TDWP Announces Deal with Summit Next Gen and Provides a Strategic Update more »
-
Top Rental Management Software (2024): TurboTenant Property Management Software Reviewed by Compare Before BuyingBOSTON--(BUSINESS WIRE)--Compare Before Buying has released an in-depth evaluation of TurboTenant, a prominent property management software, as part of its 2024 roundup of top rental management sol... more »
-
Best Property Management Software (2024): Top Rental Management Software Ranked by Compare Before BuyingBOSTON--(BUSINESS WIRE)--As rental property management becomes fast-paced and dynamic, selecting the right software can significantly enhance operational efficiency and tenant satisfaction. Compare... more »
-
Australia’s Leading Telehealth Platform, Dial A Vet, Offers 24/7 Access to Veterinarians for 7 Million HouseholdsBRISBANE, Australia--(BUSINESS WIRE)--Dial A Vet, Australia's leading veterinary telehealth platform, today announced that it is ready to serve 7 million households nationwide, providing 24/7 onlin... more »
-
ATLANTA--(BUSINESS WIRE)--Guardian Pharmacy Services, Inc. (“Guardian”) today announced the pricing of its upsized initial public offering of 8,000,000 shares of Class A common stock at a public of... more »
-
AMENDMENT: Anticipated Cash NOI** Range for Fiscal Year 2024 Should Have Been Stated as $273 Million to $278 Million; Primaris REIT Announces Acquisition of Market Leading Regional Shopping Centre, Les Galeries de la CapitaleTORONTO--(BUSINESS WIRE)--Primaris Real Estate Investment Trust (“Primaris” or the “REIT” or the “Trust”) (TSX: PMZ.UN) announced today that it has agreed to acquire Les Galeries de la Capitale in ... more »
-
FICO Survey: Rising Acceptance of 'Liar Loans' Among Malaysian ConsumersKUALA LUMPUR, Malaysia--(BUSINESS WIRE)--(NYSE: FICO): Highlights More than half of Malaysians (55%) think it’s OK or normal for people to exaggerate their income on loan applications, significantl... more »
-
FICO Survey: Rising Acceptance of ‘Liar Loans’ Among Filipino ConsumersMANILA, Philippines--(BUSINESS WIRE)--(NYSE: FICO): Highlights Half of Filipinos (51%) think it’s OK or normal for people to exaggerate their income on loan applications, significantly more than th... more »
-
SMARTSHEET INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Smartsheet Inc. - SMARNEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Smartshee... more »